[EN] INNATE IMMUNITY KILLER CELLS TARGETING PSMA POSITIVE TUMOR CELLS<br/>[FR] CELLULES TUEUSES D'IMMUNITÉ NATURELLE CIBLANT DES CELLULES TUMORALES POSITIVES AU PSMA
申请人:SORRENTO THERAPEUTICS INC
公开号:WO2021178890A1
公开(公告)日:2021-09-10
The present disclosure provides an innate immunity cell such as a gamma delta T (gdT) cell, Natural Killer (NK) cell, or macrophage having 2-[3-(1,3-dicarboxypropyl)ureido] pentanedioic acid (DUPA) chemically conjugated to the cell surface. The DUPA-conjugated cells provided herein demonstrate increased cytotoxicity toward cancer cells expressing PSMA. DUPA-conjugated cells can be primary cells or cells of a cell line. Also provided are methods of conjugating DUPA to the surface of NK cells, gamma delta T (gdT) cells, or macrophages and methods of treating cancer using DUPA-conjugated NK cells, gamma delta T (gdT) cells, or macrophages.
本公开提供了一种天然免疫细胞,例如伽玛-三角洲T(gdT)细胞、自然杀伤(NK)细胞或巨噬细胞,其表面化学偶联有2-[3-(1,3-二羧基丙基)脲基]戊二酸(DUPA)。本文所提供的DUPA偶联细胞对表达PSMA的癌细胞表现出增强的细胞毒性。DUPA偶联细胞可以是原代细胞或细胞系的细胞。还提供了将DUPA偶联到NK细胞、gdT细胞或巨噬细胞表面的方法,以及使用DUPA偶联NK细胞、gdT细胞或巨噬细胞治疗癌症的方法。